SCIENTIFIC PROGRAMME

Sunday 2 November

SS1	**11.00–12.00**	**Industry Symposium**
	12.00–13.00	**Lunch**
WS1	13.00–15.00	**Managing Patients on Multiple Co-medications**
		In collaboration with The University of Liverpool Drug Interactions Website: www.hiv-druginteractions.org
WS1CH WS1CH		Co-Chairs: *David Back, University of Liverpool, Liverpool, UK* *Saye Khoo, University of Liverpool, Liverpool, UK*
WS1CH	13.00–13.05	**Welcome and Introduction** *David Back*
WS11	13.05–13.30	**Debate: DDIs will not be a concern in 2015** *Jonathan Schapiro, National Hemophilia Center, Tel Aviv, Israel* *Manuel Battegay, University Hospital Basel, Basel, Switzerland* *Case presentations led by Saye Khoo. The panel will consist of Saye Khoo, Sanjay Bhagani, Marta Boffito and Kelly Dooley*
WS12	13.30–13.55	**Case 1: HIV–HCV co-infection** *Sanjay Bhagani, Royal Free Hospital, London, UK*
WS13	13.55–14.20	**Case 2: Recreational drugs and ARVs** *Marta Boffito, Chelsea and Westminster Hospital, London, UK*
WS14	14.20–14.45	**Case 3: TB therapy (including MDR and XDR TB) and ARVs** *Kelly Dooley, Johns Hopkins University School of Medicine, Baltimore, USA*
WS11	14.45–14.55	**Debate revisited: any change of mind?** *Jonathan Schapiro and Manuel Battegay*
WS1CH	14.55–15.00	**Closing remarks** *David Back*
	15.00–15.30	**Coffee**
SS2	15.30–17.00	**Industry Symposium**
	17.00–17.30	**Coffee**
	17.30–17.45	**Official Opening**
		Ian Weller, University College London, London, UK **Welcome from Glasgow City** *Lord Provost Sadie Docherty, Glasgow City Council*
	17.45–17.55	**Presentation of Thai Scholarship in Memory of Khanakporn Satjawat**
		Ian Weller and Praphan Phanuphak, Thai Red Cross, Bangkok, Thailand

	17.55–18.30	**Joep Lange and Jacqueline van Tongeren Memorial Lecture**
		Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of their commitment and passion to rid the world of HIV/AIDS
		Introduction *Peter Reiss, Academic Medical Center, University of Amsterdam and HIV Monitoring Foundation, Amsterdam, The Netherlands*
KL1	18.00–18.30	**Curbing the epidemic on both sides of the Atlantic: a public health perspective** *Kevin A Fenton, Health and Wellbeing, Public Health England, London, UK*
KL	18.00–19.30	**Keynote Lectures**
KLCH		Chair: *Ian Weller, University College London, London, UK*
KL2	18.30–19.00	**Mechanisms underlying abnormalities of immune activation/ coagulation in HIV infection** *Clifford Lane, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA*
KL3	19.00–19.30	**30 years of HIV: what have we learnt** *Brian Gazzard, Chelsea and Westminster Hospital, London, UK*
	19.30–20.30	**Welcome Reception**

Monday 3 November

O11	08.30–09.35	**Inflammation and Immune Recovery**
O11CH O11CH		Co-Chairs: *Daniel Kuritzkes, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA* *Jan van Lunzen, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany*
O111	08.30–08.50	**Towards an HIV cure** *Steve Deeks, University of California, San Francisco, USA*
O112*	08.50–09.05	**Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection** *John Thornhill, Imperial College London, London, UK*
O113*	09.05–09.20	**CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression** *Dominique Costagliola, INSERM and Sorbonne Universités, UPMC Université, Paris, France*
O114*	09.20–09.35	**Determinants of IL-6 levels during HIV infection** *Álvaro Borges, Copenhagen HIV Programme (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark*

*Please see pages 21–27 for full author details of oral papers

O12	09.35–10.00	**Investing in the Future: The Work of the Congress HIV Research Trust**
O12CH	09.35–09.40	**Introduction** *Robert Souhami, Chair, HIV Research Trust*
O121	09.40–10.00	**Orphans of the HIV epidemic: the challenges from toddlerhood to adolescence and beyond . . .** *Mamatha Lala, Committed Communities Development Trust; Wadia Group of Hospitals; Mumbai Smiles; Society for Human and Environmental Development, Mumbai, India*
	10.00–10.30	**Coffee**
O13	10.30–11.15	**ART and Reproductive Health**
O13CH O13CH		Co-Chairs: *Di Gibb, Medical Research Council Clinical Trials Unit, London, UK* *Elizabeth Bukusi, Kenya Medical Research Institute, Nairobi, Kenya*
O131*	10.30–10.45	**Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant** *Kimberly Scarsi, University of Nebraska Medical Center, Omaha, USA*
O132*	10.45–11.00	**Darunavir pharmacokinetics throughout pregnancy and postpartum** *John Lambert, Mater and Rotunda Hospitals, and University College Dublin, Dublin, Ireland*
O133*	11.00–11.15	**Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women?** *Susie Huntington, University College London, London, UK*
O14	11.15–12.00	**Lock Lecture**
O14CH	11.15–11.20	**Introduction** *Francis Dunn CBE, President, Royal College of Physicians and Surgeons of Glasgow, Glasgow, UK*
O141	11.20–12.00	**From guidelines to action: implementation opportunities and realities** *Wafaa El-Sadr, ICAP, Columbia University Mailman School of Public Health New York, USA*
	12.00–12.15	**Ian Weller – Vote of Thanks**
		Kevin M De Cock, US Centers for Disease Control and Prevention's Center for Global Health, Atlanta, USA
	12.15–13.30	**Poster Discussion Sessions, Scientific Posters and Lunch**

*Please see pages 21–27 for full author details of oral papers

	12.15–13.05	**Poster Discussions: Treatment Strategies**	**Clyde**
PCH PCH		Co-Chairs: *Praphan Phanuphak, Thai Red Cross, Bangkok, Thailand* *Abdel Babiker, MRC Clinical Trials Unit, University College London, London, UK*	
P291	12.15–12.25	**The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART** *Ward De Spiegelaere, Ghent University Hospital, Ghent, Belgium*	
P288	12.25–12.35	**The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART** *Sarah Fidler, Imperial College London, London, UK*	
P233	12.35–12.45	**Tolerability is more important than simplicity for treatment durability** *Benoit Trottier, Clinique Médicale l'Actuel, Montreal, Canada*	
P019	12.45–12.55	**Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial** *Sébastien Gallien, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France*	
P051	12.55–13.05	**Should the dose of tenofovir be reduced to 200–250mg/day, when combined with protease inhibitors?** *Andrew Hill, University of Liverpool, Liverpool, UK*	
	12.15–13.05	**Poster Discussions: Cost-effectiveness. STDs and PReP**	**Lomond**
PCH PCH		Co-Chairs: *Ray Fox, Gartnavel General Hospital, Glasgow, UK* *Marco Vitoria, World Health Organization, Geneva, Switzerland*	
P071	12.15–12.25	**Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r + 3TC for initial ART in HIV-infected adults** *José M Gatell, Hospital Clinic-IDIBAPS, Barcelona, Spain*	
P072	12.25–12.35	**Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa** *Andrew Hill, University of Liverpool, Liverpool, UK*	
P198	12.35–12.45	**Two years of Truvada for pre-exposure prophylaxis utilization in the US** *Charlene Flash, Baylor College of Medicine, Houston, USA*	
P121	12.45–12.55	**Increased incidence of sexually transmitted diseases (STD) in the recent years: data from the ICONA cohort** *Antonella Cingolani, Catholic University, Rome, Italy*	
P001	12.55–13.05	**Socio-economic factors and virological suppression among people diagnosed with HIV in the UK: results from the ASTRA study** *Lisa Burch, University College London, London, UK*	

O15	13.30–15.00	**First-Line Treatment Issues**
O15CH O15CH		Co-Chairs: *Anton Pozniak, Chelsea and Westminster Hospital, London, UK* *Mauro Schechter, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil*
O151	13.30–13.50	**Choice of initial therapy** *Manuel Battegay, University Hospital Basel, Basel, Switzerland*
O152	13.50–14.10	**Managing first-line failure** *David Cooper, University of New South Wales, Sydney, Australia*
O153*	14.10–14.25	**Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-infected individuals: 96-week results from FLAMINGO** *Jean-Michel Molina, Saint-Louis Hospital and University of Paris, Paris, France*
O154*	14.25–14.40	**More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV cohort** *Casper Rokx, Erasmus University Medical Center, Rotterdam, The Netherlands*
	14.40–15.00	**Panel discussion**
CS1	15.00–16.30	**Antiretroviral Therapy: Case Session**
		Case-based discussion held in collaboration with the International Antiviral Society-USA (IAS-USA) Moderator: *Roy Gulick, Weill Medical College of Cornell University, New York, USA*
	15.00–15.30	**Case 1: When and what to start** *Pedro Cahn, Fundación Huesped, Buenos Aires, Argentina*
	15.30–16.00	**Case 2: Treatment-experienced patient** *William Powderly, Washington University School of Medicine, St Louis, USA*
	16.00–16.30	**Case 3: Pre-exposure prophylaxis** *Jean-Michel Molina, Saint-Louis Hospital and University of Paris, Paris, France* Panel: *Pedro Cahn* *Simon Collins, UK Community Advisory Board (UK-CAB)/i-Base, UK* *Roy Gulick* *James Hakim University of Zimbabwe, Harare, Zimbabwe* *Jean-Michel Molina* *Cristina Mussini, University of Modena, Modena, Italy* *William Powderly*
	16.30–17.00	**Coffee**
SS3	17.00–18.30	**Industry Symposium**

*Please see pages 21–27 for full author details of oral papers

Tuesday 4 November 2014

O21	08.30–10.45	**Making Resources for Healthcare Count: What is the Optimal Way of Managing HIV?**
		In collaboration with the British HIV Association (BHIVA)
O21CH O21CH		Co-Chairs: *David Asboe, Chelsea and Westminster Hospital, London, UK* *Peter Reiss, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands*
O21CH	08.30–08.35	**Welcome and introduction** *David Asboe*
O211	08.35–08.55	**Rational allocation of resources available for healthcare: understanding cost-effectiveness analysis** *Andrew Briggs, University of Glasgow, Glasgow, UK*
O212	08.55–09.05	**The challenge: streamlining HIV treatment and care while improving outcomes** *Nathan Clumeck, Free University of Brussels, Brussels, Belgium*
O213	09.05–09.25	**Models of care and delivery** *Jens Lundgren, University of Copenhagen, Copenhagen, Denmark*
O214	09.25–09.35	**Integrated care pathways and task shifting** *Linda Panton, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK*
O215	09.35–09.45	**Enhancing patient self-management** *Alain Volny-Anne, Paris, France*
O216*	09.45–10.00	**Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018** *Andrew Hill, University of Liverpool, Liverpool, UK*
O217*	10.00–10.15	**Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients** *Simon Walker, Centre for Health Economics, University of York, York, UK*
	10.15–10.45	**Panel discussion**
	10.45–11.15	**Coffee**
O22	11.15–12.00	**Hepatitis C**
O22CH O22CH		Co-Chairs: *Tracy Swan, Treatment Action Group, New York, USA* *Jürgen Rockstroh, University of Bonn, Bonn, Germany*
O221	11.15–11.35	**Hepatitis C, from screening to treatment, a revolution** *Karine Lacombe, Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France*

*Please see pages 21–27 for full author details of oral papers

O222*	11.35–11.50	**Safety and efficacy of ombitasvir-450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens** *Roger Trinh, Antiviral Global Project Team, AbbVie Inc., North Chicago, USA*
	11.50–12.00	**Discussion**
	12.00–13.45	**Community Session, Scientific Posters and Lunch**
CoS1	12.00–13.15	**Great New Hepatitis C Drugs – But Who Can Afford Them?** **Clyde**
		In collaboration with the European AIDS Treatment Group (EATG)
CoS1CH		Co-Chairs: *Brian West, European AIDS Treatment Group, Brussels, Belgium and Edinburgh, UK*
CoS1CH		*Tracy Swan, Treatment Action Group, New York, USA*
CoS1CH	12.00–12.10	**Welcome, introduction and overview of where we are with new hepatitis C direct acting antiretrovirals** *Tracy Swan*
CoS11	12.10–12.25	**What issues are there to access to new drugs in Southern Europe** *Diego García, European AIDS Treatment Group, Brussels, Belgium and Foro Español de Activistas en Tratamientos del HIV (FEAT), Seville, Spain*
CoS12	12.25–12.40	**What issues are there to access to new drugs from a Pan-Asian perspective** *Umesh Sharma, Asian Network of People who Use Drugs, Manipur, India*
CoS13	12.40–12.55	**Issues in relation to generics and their availability and use** *Pauline Londeix, Médecins du Monde; ACT UP-Basel; and the International Treatment Preparedness Coalition (ITPC), Paris, France*
	12.55–13.10	**Panel discussion**
CoSCH	13.10–13.15	**Closing remarks** *Brian West*
O23	13.45–16.30	**When East Meets West: Issues for HIV Care Across Europe**
		In collaboration with the International AIDS Society (IAS)
O23CH		Co-Chairs: *Jens Lundgren, University of Copenhagen, Copenhagen, Denmark*
O23CH		*Elly Katabira, International AIDS Society, Geneva, Switzerland and Makerere University, Kampala, Uganda*
O231	13.45–14.05	**Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia** *Michel Kazatchkine, United Nations Special Envoy for HIV/AIDS in Eastern Europe and Central Asia, Geneva, Switzerland*
O232	14.05–14.25	**HIV epidemic in Russia and neighbouring countries** *Vadim Pokrovskiy, Federal AIDS Centre, Moscow, Russia*
O233	14.25–14.45	**Treatment and care of TB across Europe** *Ole Kirk, Centre of Health and Infectious Disease Research, University of Copenhagen, Copenhagen, Denmark*

*Please see pages 21–27 for full author details of oral papers

O234*	14.45–15.00	**Regional differences in self-reported HIV care and management in the EuroSIDA study** *Kamilla Grønborg Laut, CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark*
O235*	15.00–15.15	**Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America** *Anne Marie W Efsen, Copenhagen Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark*
O236*	15.15–15.30	**The cascade of HIV care in Russia, 2011–2013** *Anastasia Pokrovskaya, Central Scientific Research Institute of Epidemiology, Russian Federal AIDS Centre, Moscow, Russian Federation*
O237*	15.30–15.45	**Large disparities in HIV treatment cascades between eight European and high-income countries – analysis of break points** *Alice Raymond, Imperial College London, London, UK*
O23PL	15.45–16.30	**Panel discussion** Session speakers, joined by *Andrzej Horban, Warsaw Medical University and Hospital of Infectious Diseases, Warsaw, Poland*
	16.30–17.00	**Coffee**
SS4	17.00–18.30	**Industry Symposium**
	18.30–19.30	**Poster Reception**

Wednesday 5 November 2014

O31	08.30–10.00	**Co-morbidities and Complications Part I**
O31CH O31CH		Co-Chairs: *Christine Katlama, Hôpital Pitié-Salpêtrière, Paris, France* *Antonella d'Arminio Monforte, University of Milan, San Paolo Hospital, Milan, Italy*
O311	08.30–08.50	**Management of drug resistant TB in patients with HIV co-infection** *Graeme Meintjes, University of Cape Town, Cape Town, South Africa*
O312*	08.50–09.05	**CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-infected persons seen for care in Italy** *Giordano Madeddu, Unit of Infectious Diseases, University of Sassari, Sassari, Italy*
O313*	09.05–09.20	**Predictive value of Prostate Specific Antigen for prostate cancer: a nested case control study in EuroSIDA** *Leah Shepherd, University College London, London, UK*
O314*	09.20–09.35	**Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK** *Jennifer McGowan, University College London, London, UK*

*Please see pages 21–27 for full author details of oral papers

O315*	09.35–09.50	**Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study** *Colette Smith, University College London, London, UK*
	09.50–10.00	**Panel discussion**
	10.00–10.30	**Coffee**
O32	10.30–12.00	**Co-morbidities and Complications Part II**
O32CH O32CH		Co-Chairs: *Caroline Sabin, University College London, London, UK* *Ian Williams, University College London, London, UK*
O321	10.30–10.50	**Adverse events: ART and the kidney: alterations in renal function and renal toxicity** *Frank Post, King's College London, London, UK*
O322*	10.50–11.05	**A clinically useful risk-score for chronic kidney disease in HIV infection** *Amanda Mocroft, University College London, London, UK*
O323*	11.05–11.20	**Cardiovascular risk evaluation of HIV-infected patients in a case control study: comparison of the D:A:D and Framingham equations** *Samuel Markowicz, CHU Saint-Pierre, Brussels, Belgium*
O324*	11.20–11.35	**Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study** *Camilla Ingrid Hatleberg, Rigshospitalet, University of Copenhagen, CHIP, Department of Infectious Diseases, Copenhagen, Denmark*
	11.35–12.00	**Panel discussion**
	12.00–13.45	**Poster Discussion Sessions, Scientific Posters and Lunch**
	12.15–13.15	**Poster Discussions: Adverse Events** **Clyde**
PCH PCH		Co-Chairs: *Simon Mallal, Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia* *Alejandro Arenas-Pinto, MRC Clinical Trials Unit, University College London, London, UK*
P018	12.15–12.25	**Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC** *Roger Paredes, Hospital Universitari Germans Trias i Pujol, IrsiCaixa Foundation, Universitat de Vic, Barcelona, Spain*
P010	12.25–12.35	**Rates of cardiovascular events and deaths are associated with advanced stages of HIV-infection: results of the HIV HEART Study 7.5-year follow-up** *Stefan Esser, University Hospital Essen, Dermatology and Venerology, Essen, Germany*
P020	12.35–12.45	**Higher rates of metabolic syndrome among women taking zidovudine as compared to tenofovir in rural Africa: preliminary data from the CART-1 study** *Niklaus Daniel Labhardt, Swiss Tropical and Public Health Institute, Department of Medical and Diagnostic Services, Basel, Switzerland*

*Please see pages 21–27 for full author details of oral papers

P039	12.45–12.55	**Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice** *Silvia Costarelli, San Gerardo Hospital, Infectious Diseases, Monza, Italy*
P028	12.55–13.05	**Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens** *Angelina Villasis Keever, Bristol-Myers Squibb, Plainsboro, USA*
P021	13.05–13.15	**Long-term fat redistribution in ARV-naïve HIV+ pts initiating a non-thymidine containing regimen in clinical practice** *Elena Ferrer, Hospital Universitari de Bellvitge, Infectious Diseases, Barcelona, Spain*
	12.15–13.15	**Poster Discussions: Virology and the Brain** **Lomond**
PCH PCH		Co-Chairs: *Andrea Antinori, National Institute for Infectious Diseases, Rome, Italy* *Fujie Zhang, National Center for AIDS/STD Control and Prevention, Beijing, China*
P205	12.15–12.25	**Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure** *Anna Schultze, University College London, London, UK*
P206	12.25–12.35	**HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M** *Agnès Depatureaux, McGill AIDS Center, Lady Davis Institute, Jewish General Hospital, Montreal, Canada*
P207	12.35–12.45	**Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK** *Kate El Bouzidi, University College London, London, UK*
P289	12.45–12.55	**DRV concentrations and viral load in CSF in pts on DRV/r 600/100 or 800/100mg once daily plus two NRTI** *Daniel Podzamczer, Hospital Universitari de Bellvitge, Infectious Diseases, Barcelona, Spain*
P050	12.55–13.05	**Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600mg once daily; a randomised controlled trial** *Alan Winston, Imperial College London, London, UK*
P178	13.05–13.15	**Viro-immunological characterization of naïve patients with high cerebrospinal fluid HIV RNA** *Francesca Bai, University of Milan, San Paolo Hospital, Milan, Italy*
O33	13.45–15.00	**Resistance and Tropism**
O33CH O33CH		Co-Chairs: *Anders Sönnerborg, Karolinska Institutet, Stockholm, Sweden* *Cissy Kityo, Joint Clinical Research Centre, Kampala, Uganda*
O331	13.45–14.05	**Resistance: what's new and on the horizon, and a time to teach old dogs new tricks?** *Jonathan Schapiro, National Hemophilia Center, Tel Aviv, Israel*

O332*	14.05–14.20	**The R263K mutation in HIV integrase that is selected by dolutegravir (DTG) may actually prevent clinically relevant resistance to this compound** *Mark Wainberg, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada*
O333*	14.20–14.35	**First prospective comparison of genotypic vs. phenotypic tropism assays in predicting virologic responses to maraviroc (MVC) in a phase 3 study: MODERN** *James Demarest, ViiV Healthcare, Research Triangle Park, USA*
O334*	14.35–14.50	**Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study** *Roger Paredes, irsiCaixa AIDS Research Institute, Barcelona, Spain*
	14.50–15.00	**Panel discussion**
CS2	15.00–16.30	**Management of Co-morbidities: Case Session**

Case-based discussion held in collaboration with the European AIDS Clinical Society (EACS)

Moderators: *Nina Friis-Møller, Odense University Hospital, Odense, Denmark*
Patrick Mallon, School of Medicine & Medical Science, University College, Dublin, Ireland

Cases: **Prevention and Management of Anal Cancer**
Bone
Pulmonary Disease
Management Issues in People Who Use Drugs

Case Study Presenters: *Thilde Fabricius, Odense Unviersity Hospital, Odense, Denmark*
Deirdre Morley, Mater Misericordiae University Hospital, Dublin, Ireland

Panel: *Mark Bower, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK*
Juliet Compston, Cambridge University Hospital, Cambridge, UK
Nikos Dedes, Positive Voice, Athens, Greece
Patrick Mallon
Deborah Konopnicki, Saint-Pierre University Hospital, Brussels, Belgium
Rob Miller, University College London, London, UK
Mina Psichogiou, Athens University Medical School, Athens, Greece

	16.30–17.00	**Coffee**
SS5	17.00–18.30	**Industry Symposium**
	18.30–18.45	**Coffee**
SS6	18.45–20.15	**Industry Symposium**

*Please see pages 21–27 for full author details of oral papers

Thursday 6 November 2014

O41	08.30–09.25	**ARV-based Prevention**
O41CH O41CH		Co-Chairs: *Dominique Costagliola, INSERM and Sorbonne Universités, UPMC Université, Paris, France* *Bruno Spire, AIDES & INSERM U912, Marseille, France*
O411	08.30–08.50	**Treatment as prevention: unanswered questions and progress to date** *Stefano Vella, Istituto Superiore Di Sanità, Rome, Italy*
O412	08.50–09.10	**A community perspective on PrEP** *Simon Collins, UK Community Advisory Board (UK-CAB)/i-Base, London, UK*
	09.10–09.25	**Panel discussion**
O42	09.25–10.25	**ART Strategies**
O42CH O42CH		Co-chairs: *Margaret Johnson, Royal Free Hospital, London, UK* *Eric Sandström, Karolinska Institutet, Stockholm, Sweden*
O421*	09.25–09.40	**Efavirenz (EFV) 400mg daily remains non-inferior to 600mg: 96-week data from the double-blind, placebo-controlled ENCORE1 study** *Dianne Carey, The Kirkby Institute, University of New South Wales, Sydney, Australia*
O422*	09.40–09.55	**Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of therapeutic drug monitoring** *Chien-Ching Hung, National Taiwan University Hospital, Internal Medicine, Taipei City, Taiwan*
O423A/B*	09.55–10.10	**The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL** and **Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues** *Andrea Antinori, National Institute of Infectious Diseases, Rome, Italy*
O424*	10.10–10.25	**Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study** *Jemma O'Connor, University College London, London, UK*
	10.25–10.55	**Coffee**
O43	10.55–12.00	**New HIV Drugs**
O43CH O43CH		Co-Chairs: *Cristina Mussini, University of Modena, Modena, Italy* *Mark Nelson, Chelsea and Westminster Hospital, London, UK*
O431	10.55–11.15	**HIV treatment 2020: what will it look like?** *Roy Gulick, Weill Medical College of Cornell University, New York, USA*

*Please see pages 21–27 for full author details of oral papers

O432A/B*	11.15–11.30	**HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 subgroup analysis** and **Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis** *Max Lataillade, HIV Drug Development, Bristol-Myers Squibb, Wallingford, USA*
O433*	11.30–11.45	**Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc** *Mark Wainberg, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada*
O434*	11.45–12.00	**48-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naïve HIV-Infected patients** *José Gatell, Hospital Clinic, University of Barcelona, Barcelona, Spain*
	12.00–12.10	**Closing Remarks** *Andrew Phillips, University College London, London, UK* *Brian West, European AIDS Treatment Group (EATG), Brussels, Belgium and Edinburgh, UK*
12.10–13.00		**Lunch and Depart**

*Please see pages 21–27 for full author details of oral papers

Submitted abstracts accepted for oral presentation within the main programme, illustrating full author group and affiliations

Monday 3 November 2014

O112 **Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection**

John Thornhill[1]; Jamie Inshaw[2]; Soonita Oomeer[1]; Pontiano Kaleebu[3]; David Cooper[4]; Gita Ramjee[5]; Mauro Schechter[6]; Giuseppe Tambussi[7]; Julie Fox[8]; Jose Maria Miro[9]; Jonathan Weber[1]; Abdel Babiker[2]; Kholoud Porter[2]; Sarah Fidler[1]

[1]Department of Medicine, Imperial College, London, UK;[2]MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK; [3]Medical Research Council, Uganda Virus Research Institute, Entebbe, Uganda; [5]Kirby Institute, University of New South Wales, Sydney, Australia; 6HIV Prevention Unit, Medical Research Council, Durban, South Africa; [7]Hospital Escola Sao Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; [8]Division of Infectious Diseases, Ospedale San Raffaele, Milan, Italy; [9]Guys and St Thomas' NHS Trust, Kings College London, London, UK; [10]Hospital Clinic, University of Barcelona, Barcelona, Spain

O113 **CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression**

Dominique Costagliola[1]; Jean-Marc Lacombe[1]; Jade Ghosn[2]; Constance Delaugerre[3]; Gilles Pialoux[4]; Lise Cuzin[5]; Odile Launay[6]; Amélie Ménard[7]; Pierre de Truchis[8]; Murielle Mary-Krause[1]; Laurence Weiss[9]; Jean-François Delfraissy[10]

[1]INSERM and Sorbonne Universités, UPMC Université Paris 6, Paris, France; [2]AP-HP, Hotel-Dieu, Université Paris Descartes, Paris, France; [3]AP-HP, Hôpital Saint-Louis, Université Paris Diderot et INSERM, Paris, France; [4]AP-HP, Hôpital Tenon, Service de Maladies Infectieuses, Paris, France; [5]CHU Toulouse, Service de Maladies Infectieuses, Toulouse, France; [6]AP-HP, Hôpital Cochin, Fédération d'Infectiologie, Paris, France; [7]AP-HM, Hôpital de la Conception, Service de Maladies Infectieuses, Marseille, France; [8]AP-HP, Hôpital Raymond Poincaré, Service de Maladies Infectieuses, Paris, France; [9]AP-HP, Hôpital Européen Georges Pompidou, Institut Pasteur, France; [10]ANRS, Paris, France

O114 **Determinants of IL-6 levels during HIV infection**

Álvaro Borges[1]; Jemma O'Connor[2]; Andrew Phillips[2]; Frederikke Rönsholt[3]; Sarah Pett[4,5]; Michael Vjecha[6]; Martyn French[7]; Jens Lundgren[1]

[1]Rigshospitalet, University of Copenhagen, CHIP, Department of Infectious Diseases & Rheumatology, Copenhagen, Denmark; [2]University College London, Research Department of Infection and Population, London, UK; [3]Rigshospitalet, University of Copenhagen, Department of Infectious Diseases, Copenhagen, Denmark; [4]University College London, MRC Clinical Trials Unit, London, UK; [5]Kirby Institute, University of New South Wales Australia, Sydney, Australia; [6]Veterans Affairs Medical Center, Institute for Clinical Research, Washington, USA; [7]Royal Perth Hospital & PathWest Laboratory, Department of Clinical Immunology, Perth, Australia

O131 **Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant**

Kimberly Scarsi[1]; Mohammed Lamorde[2]; Kristin Darin[3]; Sujan Dilly Penchala[4]; Laura Else[4]; Shadia Nakalema[2]; Pauline Byakika-Kibwika[2]; Saye Khoo[4]; Susan Cohn[3]; Concepta Merry[5]; David Back[4]

[1]University of Nebraska Medical Center, Department of Pharmacy Practice, Omaha, USA; [2]Makerere University College of Health Sciences, Infectious Diseases Institute, Uganda; [3]Northwestern University Feinberg School of Medicine, Division of Infectious Diseases, USA; [4]University of Liverpool, Department of Molecular and Clinical Pharmacology, UK; [5]Trinity College Dublin, Department of Pharmacology and Therapeutics, Dublin, Ireland

O132 **Darunavir pharmacokinetics throughout pregnancy and postpartum**

John Lambert[1]; Valerie Jackson[1]; Laura Else[2]; Mairead Lawless[1]; Grainne McDonald[3]; DaveLe Blanc[3]; Anjali Patel[4]; Kelly Stephens[4]; Saye Khoo[5]

[1]The Rotunda Hospital, Infectious Diseases, Dublin, Ireland; [2]Royal Liverpool University Hospital, Bioanalytical Facility, Liverpool, UK; [3]The Rotunda Hospital, Laboratory Medicine, Dublin, Ireland; [4]Mater Misericordiae University Hospital, Catherine McAuley Clinical Research Centre, Dublin, Ireland; [5]Royal Liverpool University Hospital, Molecular and Clinical Pharmacology, Liverpool, UK

O133 **Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women?**

Susie Huntington[1]; Claire Thorne[2]; Jane Anderson[3]; Marie-Louise Newell[4]; Graham Taylor[5]; Deenan Pillay[1]; Teresa Hill[1]; Pat Tookey[2]; Caroline Sabin[1]

[1]University College London, Research Department of Infection & Population Health, London, UK; [2]Uniersity College London, Institute of Child Health, Population, Policy and Practice Programme, London, UK; [3]Homerton University Hospital NHS Foundation Trust, London, UK; [4]University of Southampton, Human Development and Health, Southampton, UK; [5]Imperial College, Faculty of Medicine, London, UK

O153 **Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-infected individuals: 96-week results from FLAMINGO**

Jean-Michel Molina[1]; Bonaventura Clotet[2]; Jan van Lunzen[3]; Adriano Lazzarin[4]; Matthias Cavassini[5]; Keith Henry[6]; Valeriv Kulagin[7]; Naomi Givens[8]; Clare Brennan[9]; Carlos Fernando de Oliveira[10]

[1]Hôpital Saint Louis, Service des Maladies, Infectieuses et Tropicales, Paris, France; [2]Hospital Universitari Germans Trias i Pujol, HIV Unit. Irsicaixa Foundation. UAB. UVIC-UCC, Barcelona, Spain; [3]University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg, Germany; [4]IRCCS San Raffaele Via Stamira d'Ancona, Department of Infectious Diseases, Milan, Italy; [5]Lausanne University Hospital, Infectious Disease Service, Lausanne, Switzerland; [6]Hennepin County Medical Center, Department of Medicine, Minneapolis, USA; [7]Clinical Center for Prevention and Control of AIDS, Krasnodar, Russian Federation; [8]GlaxoSmithKline, Clinical Statistics, London, UK; [9]GlaxoSmithKline, Infectious Disease, Clinical Development, Research Triangle Park, USA; [10]PPD, Pharmacovigilance, Morrisville, USA

O154 **More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV cohort**

Casper Rokx[1]; Azzania Fibriani[2]; David van de Vijver[2]; Annelies Verbon[1]; Martin Schutten[2]; Luuk Gras[3]; Bart J.A. Rijnders[1]

[1]Erasmus University Medical Center, Department of Internal Medicine, Rotterdam, The Netherlands; [2]Erasmus University Medical Center, Department of Virology, (City), The Netherlands; [3]On behalf of the ATHENA National Observational Cohort study. Dutch HIV Monitoring Foundation, Research Department, Amsterdam, The Netherlands

Tuesday 4 November 2014

O216 **Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018**

Andrew Hill[1]; Teresa Hill[2]; Sophie Jose[2]; Anton Pozniak[3]

[1]University of Liverpool, Pharmacology and Therapeutics, Liverpool, UK; [2]University College London, Infection and Population Health, London, UK; [3]Chelsea and Westminster Hospital, St Stephens Centre, London, UK

O217 **Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients**

Lars Oddershede[1]; Simon Walker[2]; Nicholas Paton[3]; Wolfgang Stöhr[3]; David Dunn[3]; Mark Sculpher[2]

[1]Aalborg University, Danish Center for Healthcare Improvements, Aalborg East, Denmark; [2]University of York, Centre for Health Economics, York, UK; [3]UCL, MRC Clinical Trials Unit, London, UK

O222 **Safety and efficacy of ombitasvir-450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens**

Joseph Eron[1]; Jay Lalezari[2]; Jihad Slim[3]; Joseph Gathe[4]; Peter Ruane[5]; Chia Wang[6]; Richard Elion[7]; Gary Blick[8]; Amit Khatri[9]; Yiran Hu[10]; Krystal Gibbons[11]; Linda Fredrick[10]; Melannie Co[12]; Ronald D'Amico[13]; Barbara Da Silva-Tillmann[14]; Roger Trinh[15]; Mark Sulkowski[16]

[1]University of North Carolina, Division of Infectious Diseases, Chapel Hill, USA; [2]Quest Clinical Research, Medical Director, San Francisco, USA; [3]St. Michael's Medical Center, Infectious Disease Medicine, Newark, USA; [4]Cure C. Consortium, Infectious Disease, Houston, USA; [5]Peter J. Ruane, MD, Inc., Infectious Disease, Los Angeles, USA; [6]Virginia Mason Medical Center, Infectious Diseases, Seattle, USA; [7]Whitman-Walker Health, Clinical Medicine, Washington DC, USA; [8]CIRCLE CARE Center, Infectious Diseases, Norwalk, USA; [9]AbbVie Inc., Clinical Pharmacokinetics, North Chicago, USA; [10]AbbVie Inc., Statistics, North Chicago, USA; [11]AbbVie Inc., Clinical Research Management, North Chicago, USA; [12]AbbVie Inc., Medical Review, North Chicago, USA; [13]AbbVie Inc., Medical Affairs, North Chicago, USA; [14]AbbVie Inc., Medical Safety Evaluation, North Chicago, USA; [15]AbbVie Inc., Infectious Diseases, North Chicago, USA; [16]Johns Hopkins University, Viral Hepatitis Center, Baltimore, USA

O234 **Regional differences in self-reported HIV care and management in the EuroSIDA study**

Kamilla Grønborg Laut[1]; Amanda Mocroft[2]; Jeffrey Lazarus[1]; Peter Reiss[3]; Jürgen Rockstroh[4]; Igor Karpov[5]; Aza Rakhmanova[6]; Brygida Knysz[7]; Santiago Moreno[8]; Panagiotis Gargalianos[9]; Jens Lundgren[1]; Ole Kirk[1]; on behalf of EuroSIDA in EuroCoord[1]

[1]Rigshospitalet, University of Copenhagen, CHIP at Department of Infectious Diseases, Copenhagen, Denmark; [2]University College London, Department of Infection and Population Health, London, UK; [3]University of Amsterdam and Stichting HIV Monitoring, Academic Medical Center, Amsterdam, The Netherlands; [4]University Hospital Bonn, Immunologische Ambulanz, Bonn, Germany; [5]Belarus State Medical University, Department of Infectious Diseases, Minsk, Belarus; [6]Botkin Hospital of Infectious Diseases, Department 21, St Petersburg, Russian Federation; [7]Wroclaw University School of Medicine, Department of Infectious Diseases, Warsaw, Poland; [8]Hospital Ramon y Cajal, Servicio Enfermedades Infecciosas, Madrid, Spain; [9]G Gennimatas Hospital, 1st Internal Medicine Department Infectious Diseases Unit, Athens, Greece

O235 **Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America**

Anne Marie Efsen[1]; Anna Schultze[2]; Frank Post[3]; Alexander Panteleev[4]; Hansjakob Furrer[5]; Robert Miller[6]; Aliaksandr Skrahin[7]; Marcelo Losso[8]; Javier Toibaro[8]; Enrico Girardi[9]; José Miro[10]; Mathias Bruyand[11]; Niels Obel[12]; Joan Caylá[10]; Daria Podlekareva[1]; Jens Lundgren[1]; Amanda Mocroft[2]; Ole Kirk[1]; in EuroCoord TB/HIV Study Group[1]

[1]Rigshospitalet, University of Copenhagen, CHIP, Department of Infectious Disease and Rheumatology, Copenhagen, Denmark; [2]University College London, Department of Infection and Population Health, London, UK; [3]King's College Hospital, Department of Sexual Health, London, UK; [4]City TB Hospital 2, HIV/TB, St Petersburg, Russian Federation; [5]Bern University Hospital and University of Bern, Department of Infectious Diseases, Bern, Switzerland; [6]University College London, Centre for Sexual Health and HIV Research, London, UK; [7]Republican Research and Practical Centre for Pulmonary and TB, Clinical Department, Belarus; [8]Hospital Gral. de Agudos JM Ramos Mejía, Servicio Inmunocomprometidos, Argentina; [9]Istituto Nazionale Malattie Infettive L. Spallanzani - IRCCS, UOC Epidemiologia Clinica, Rome, Italy; [10]Hospital Clinic Universitari de Barcelona, Hospital Clinic Universitari, Spain; [11]Université Bordeaux Segalen, INSERM U897, Bordeaux, France; [12]Rigshospitalet, University of Copenhagen, Department of Infectious Diseases and Rheumatology, Copenhagen, Denmark

O236 **The cascade of HIV care in Russia, 2011–2013**

Anastasia Pokrovskaya; Anna Popova; Natalia Ladnaya; Oleg Yurin

Central Scientific Research Institute of Epidemiology, Russian Federal AIDS Centre, Moscow, Russian Federation

O237 **Large disparities in HIV treatment cascades between eight European and high-income countries – analysis of break points**

Alice Raymond[1]; Andrew Hill[2]; Anton Pozniak[3]

[1]Imperial College London, Department of Public Health, London, UK; [2]Liverpool University, Molecular and Clinical Pharmacology, Liverpool, UK; [3]Chelsea and Westminster Hospital, St Stephens Centre, London, UK

Wednesday 5 November 2014

O312 **CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-infected persons seen for care in Italy**

Giordano Madeddu[1]; Antonella d'Arminio Monforte[2]; Enrico Girardi[3]; Antonio Di Biagio[4]; Sergio Lo Caputo[5]; Roberta Piolini[6]; Giulia Marchetti[2]; Giampietro Pellizzer[7]; Andrea Giacometti[8]; Laura Galli[9]; Andrea Antinori[10]; Alessandro Cozzi Lepri[11]; on behalf of ICONA Foundation Study[12]

[1]University of Sassari, Unit of Infectious Diseases, Sassari, Italy; [2]University of Milan, San Paolo Hospital, Health Sciences, Milan, Italy; [3]National Institute for Infectious Diseases, Clinical Epidemiology, Rome, Italy; [4]IRCCS San Martino Hospital, Infectious Diseases, Genoa, Italy; [5]Santa Maria Annunziata Hospital, Infectious Diseases, Florence, Italy; [6]University of Milan, Luigi Sacco Hospital, Infectious Diseases, Milan, Italy; [7]Vicenza Hospital, Infectious Diseases, Vicenza, Italy; [8]Ancona Hospital, Infectious Diseases, Ancona, Italy; [9]San Raffaele Hospital, Infectious Diseases, Milan, Italy; [10]National Institute for Infectious Diseases "L. Spallanzani", Clinical Department, Rome, Italy; [11]University College London, Infection and Population Health, London, UK; [12]University of Milan, Health Sciences, Milan, Italy

O313 **Predictive value of Prostate Specific Antigen for prostate cancer: a nested case control study in EuroSIDA**

Leah Shepherd[1]; Álvaro Humberto Borges[2]; Lene Ravn[3]; Richard Harvey[4]; Jean-Paul Viard[5]; Mark Bower[6]; Andrew Grulich[7]; Michael Silverberg[8]; Stephane De Wit[9]; Ole Kirk[2]; Jens Lundgren[2]; Amanda Mocroft[1]; on behalf of Eurosida in Eurocoord[2]

[1]University College London, Department of Infection and Population Health, London, UK; [2]Rigshospitalet, University of Copenhagen, Centre for Health & Infectious Diseases Research, Copenhagen, Denmark; [3]Rigshospitalet, Department of Clinical Biochemistry, Copenhagen, Denmark; [4]Charing Cross Hospital Campus of Imperial College Healthcare National Health Service Trust, Charing Cross Oncology Laboratory and Trophoblast, London, UK; [5]Université Paris Descartes, Centre de Diagnostic et de Thérapeutique, Hôtel-D, Paris, France; [6]Chelsea and Westminster Hospital NHS Foundation Trust, National Centre for HIV Malignancy, London, UK; [7]The University of New South Wales, Kirby Institute, Sydney, Australia; [8]Kaiser Permanente Northern California, Division of Research, Oakland, USA; [9]Department of Infectious Diseases, Saint-Pierre Hospital, Brussels, Belgium

O314 **Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK**

Jennifer McGowan[1]; Lorraine Sherr[1]; Alison Rodger[1]; Martin Fisher[2]; Alec Miners[3]; Margaret Johnson[4]; Jonathan Elford[5]; Simon Collins[6]; Graham Hart[7]; Andrew Phillips[1]; Andrew Speakman[1]; Fiona Lampe[1]

[1]University College London, Infection and Population Health, London, UK; [2]Brighton and Sussex University Hospitals NHS Trust, HIV Medicine, Brighton, UK; [3]London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy, London, UK; [4]The Royal Free Centre for HIV Medicine, HIV Medicine, London, UK; [5]City University, Evidence-based Health Care, London, UK; [6]HIV i-Base, HIV i-Base, London, UK; [7]University College London, Population Health Sciences, London, UK

O315 **Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study**

Colette Smith[1]; Lene Ryom[2]; Antonella d'Arminio Monforte[3]; Peter Reiss[4]; Amanda Mocroft[1]; Wafaa El-Sadr[5]; Rainer Weber[6]; Matthew Law[7]; Caroline Sabin[1]; Jens Lundgren[2]

[1]University College London, Infection and Population Health, London, UK; [2]University of Copenhagen, CHIP, Copenhagen, Denmark; [3]San Paolo University Hospital, Health Sciences, San Paolo, Italy; [4]University of Amsterdam and Stichting HIV Monitoring, Academic Medical Center, Amsterdam, The Netherlands; [5]Columbia University, Mailman School of Public Health, New York, USA; [6]University Hospital Zurich, Division of Infectious Diseases, Zurich, Switzerland; [7]University of New South Wales, Kirby Institute, Sydney Australia

O322 **A clinically useful risk-score for chronic kidney disease in HIV infection**

Amanda Mocroft[1]; Jens Lundgren[2]; Michael Ross[3]; Matthew Law[4]; Peter Reiss[5]; Ole Kirk[2]; Colette Smith[1]; Debbie Wentworth[6]; Jacquie Heuhaus[6]; Christophe Fux[7]; Olivier Moranne[8]; Phillipe Morlat[9]; Margaret Johnson[10]; Lene Ryom[2]

[1]University College London, Department of Infection and Population Health, London, UK; [2]University of Copenhagen/ Rigshospitalet, Copenhagen HIV Programme, Department of Infectious Diseases, Copenhagen, Denmark; [3]Mount Sinai School of Medicine, Division of Nephrology, New York, USA; [4]University of New South Wales, The Kirby Institute for Infection and Immunity, Sydney, Australia; [5]University of Amsterdam, Academic Medical Centre, Division of Infectious Diseases/ Department of Global Health, Amsterdam, The Netherlands; [6]University of Minnesota, Division of Biostatistics, Minnesota, USA; [7]Kantonsspital Aarau, Clinic for Infectious Diseases and Hospital Hygiene, Aarau, Switzerland; [8]Université Bordeaux Segalen, INSERM U 897, CHU de Bordeaux, Bordeaux, France; [9]CHU Nice, Nephrology Department, Public Health Department, Nice, France; [10]Royal Free Hospital NHS Trust, Thoracic Medicine, London, UK

O323 **Cardiovascular risk evaluation of HIV-infected patients in a case control study: comparison of the D:A:D and Framingham equations**

Samuel Markowicz; Marc Delforge; Coca Necsoi; Stéphane De Wit

CHU Saint-Pierre, Brussels, Belgium

O324 **Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study**

Camilla Ingrid Hatleberg[1]; Lene Ryom[1]; Wafaa El-Sadr[2]; Amanda Mocroft[3]; Peter Reiss[4]; Stephan de Wit[5]; Francois Dabis[6]; Christian Pradier[7]; Antonella d'Arminio Monforte[8]; Martin Rickenbach[9]; Matthew Law[10]; Jens Lundgren[1]; Caroline Sabin[3]

[1]Rigshospitalet, University of Copenhagen, CHIP Department. of Infectious Diseases, Copenhagen, Denmark; [2]Columbia University, Mailman School of Public Health, New York, US; [3]University College London, Research Dept. of Infection and Population Health, London, UK; [4]Amsterdam Medical Center, University of Amsterdam, Stichting HIV Monitoring, Amsterdam, The Netherlands; [5]CHU Saint-Pierre Hospital, Saint-Pierre Cohort, Brussels, Belgium; [6]University of Bordeaux, ISPED, Centre Inserm U897, Bordeaux, France; [7]Nice University Hospital, Department of Public Health, Nice, France; [8]San Paolo University Hospital, Dept. of Health Sciences, Infectious Diseases Unit, Milan, Italy; [9]University of Lausanne, Institute of Social and Preventive Medicine, Swiss Cohort Study, Lausanne, Switzerland; [10]University of New South Wales, The Kirby Institute, Sydney, Australia

O332 **The R263K mutation in HIV integrase that is selected by dolutegravir (DTG) may actually prevent clinically relevant resistance to this compound**

Mark Wainberg; Kaitlin Anstett; Thibault Mesplede; Peter Quashie; Yingshan Han; Maureen Oliveira

McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada

O333 **First prospective comparison of genotypic vs. phenotypic tropism assays in predicting virologic responses to maraviroc (MVC) in a phase 3 study: MODERN**

Jayvant Heera[1]; Srinivas Valluri[2]; Charles Craig[3]; Annie Fang[1]; Neal Thomas[2]; Ralph Dan Meyer[2]; James Demarest[4]

[1]Pfizer Inc, Clinical Development, Groton, USA; [2]Pfizer Inc, Statistics, New York, USA; [3]Pfizer Inc, Virology, Sandwich, UK; [4]ViiV Healthcare, Virology, New York, USA

O334 **Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study**

Federico Garcia[1]; Eva Poveda[2]; Maria Jesús Pérez-Elías[3]; José Hernández Quero[1]; Maria Àngels Ribas[4]; Onofre J. Martínez-Madrid[5]; Juan Flores[6]; Manel Crespo[7]; Félix Gutiérrez[8]; Miguel García-Deltoro[9]; Arkaitz Imaz[10]; Antonio Ocampo[11]; Arturo Artero[12]; Francisco Blanco[13]; Enrique Bernal[14]; Juan Pasquau[15]; Carlos Mínguez-Gallego[16]; Núria Pérez[17]; Aintzane Aiestarán[17]; Roger Paredes[18]

[1]Hospital Universitario San Cecilio, Granada, Spain; [2]INIBIC-Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain; [3]Hospital Ramón y Cajal, Madrid, Spain; [4]Hospital Son Espases, Palma de Mallorca, Spain; [5]Hospital General Universitario Santa Lucía, Cartagena, Spain; [6]Hospital Arnau de Vilanova, Valencia, Spain; [7]Hospital Universitari Vall d'Hebron, Barcelona, Spain; [8]Hospital Universitario de Elche, Elche, Spain; [9]Hospital General Universitario de Valencia, Valencia, Spain; [10]Hospital de Bellvitge, Barcelona, Spain; [11]Hospital Xeral de Vigo, Vigo, Spain; [12]Hospital Universitario Dr. Peset, Valencia, Spain; [13]Hospital Carlos III, Madrid, Spain; [14]Hospital Reina Sofía, Murcia, Spain; [15]Hospital Virgen de la Nieves, Granada, Spain; [16]Hospital General de Castelló, Castelló, Spain; [17]Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; [18]irsiCaixa AIDS Research Institute, Barcelona, Spain

Thursday 6 November 2014

O421 **Efavirenz (EFV) 400mg daily remains non-inferior to 600mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study**

Dianne Carey

The Kirkby Institute, University of New South Wales, Sydney, Australia

O422 **Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of therapeutic drug monitoring**

Shang-Ping Yang[1]; Wen-Chun Liu[2]; Kuan-Yeh Lee[3]; Bing-Ru Wu[2]; Yi-Ching Su[2]; Pei-Ying Wu[1]; Jun-Yu Zhang[1]; Yu-Zhen Luo[1]; Hsin-Yun Sun[2]; Sui-Yuan Chang[4]; Shu-Wen Lin[5]; Chien-Ching Hung[2]

[1]National Taiwan University Hospital, Center for Infection Control, Taipei City, Taiwan; [2]National Taiwan University Hospital, Internal Medicine, Taipei City, Taiwan; [3]National Taiwan University Hospital Hsinchu Branch, Internal Medicine, Hsin-Chu City, Taiwan; [4]National Taiwan University College of Medicine, Clinical Laboratory Sciences and Medical Biotechnology, Taipei City, Taiwan; [5]College of Medicine, National Taiwan University, Graduate Institute of Clinical Pharmacy, Taipei City, Taiwan

O423A **The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL**

Andrea Antinori[1]; Jose Arribas[2]; Jan Fehr[3]; Pierre-Marie Girard[4]; Andrzej Horban[5]; Andrew Hill[6]; Yvon van Delft[7]; Christiane Moecklinghoff[8]; Andrew Hill[9]

[1]National Institute of Infectious Diseases, Infectious Diseases, Rome, Italy; [2]Hospital la Paz, IdiPAZ, (City), Spain; [3]University Hospital Zurich, Infectious Diseases, Zurich, Switzerland; [4]Hopital Saint-Antoine, Maladies Infectiueuses et Tropicales, Paris, France; [5]Warsaw Medical University, Infectious Diseases, Warsaw, Poland; [6]Janssen, R&D, High Wycombe, UK; [7]Janssen, EMEA, Tilburg, The Netherlands; [8]Janssen, EMEA, Neuss, Germany; [9]University of Liverpool, Pharmacology and Therapeutics, Liverpool, UK

O423B **Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues**

Amanda Clarke[1]; Veronika Johanssen[2]; Jan Gerstoft[3]; Bonaventura Clotet[4]; Diego Ripamonti[5]; Andrew Murungi[6]; Ceyhun Bicer[7]; Maria Blanca Hadacek[8]; Christiane Moecklinghoff[9]

[1]Brighton and Sussex Medical School, HIV and Sexual Health, Brighton, UK; [2]Karolinkska University, Infectious Diseases, Stockholm, Sweden; [3]Copenhagen University Hospital, Infectious Diseases, Copenhagen, Denmark; [4]University Hospital Germans Trias i Pujol, irsiCaixa, Barcelona, Spain; [5]University Hospital, Infectious Diseases, Bergamo, Italy; [6]Janssen, HIV, High Wycombe, UK; [7]Janssen, R&D, Beerse, Belgium; [8]Janssen, EMEA, Issy-les-Moulineux, France; [9]Janssen, EMEA, Neuss, Germany

O424 **Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study**

Jemma O'Connor[1]; Colette Smith[1]; Fiona Lampe[1]; Margaret Johnson[2]; Caroline Sabin[1]; Andrew Phillips[1]

[1]Department of Infection and Population Health, University College London, London, UK; [2]Ian Charleson Day Centre, Royal Free Hampstead NHS Trust, London, UK

O432A **HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 subgroup analysis**

Cynthia Brinson[1]; Jacob Lalezari[2]; Gulam H Latiff[3]; Melanie Thompson[4]; Juan Echevarria[5]; Sandra Treviño-Pérez[6]; David Stock[7]; Samit R Joshi[7]; George J Hanna[8]; Max Lataillade[7]

[1]Southwestern Medical School, Austin Branch and Central Texas Clinical Research, Family Medicine, Austin, USA; [2]Quest Clinical Research, San Francisco, USA; [3]Maxwell Clinic, Durban, South Africa; [4]AIDS Research Consortium of Atlanta, Atlanta, USA; [5]Hospital Nacional Cayetano Heredia, Infectious and Tropical Medicine, Lima, Peru; [6]Mexico Centre for Clinical Research, HIV Research Department, Mexico City, Mexico; [7]Bristol-Myers Squibb, Research and Development, Wallingford, USA; [8]Bristol-Myers Squibb, Research and Development, Princeton, USA

O432B **Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis**

Jacob Lalezari[1]; Gulam H Latiff[2]; Cynthia Brinson[3]; Juan Echevarria[4]; Sandra Treviño-Pérez[5]; Johannes R Bogner[6]; David Stock[7]; Samit R Joshi[7]; George J Hanna[8]; Max Lataillade[7]

[1]Quest Clinical Research, San Francisco, USA; [2]Maxwell Clinic, Durban, South Africa; [3]Southwestern Medical School, Austin Branch and Central Texas Clinical Research, Family Medicine, Austin, USA; [4]Hospital Nacional Cayetano Heredia, Infectious and Tropical Medicine, Lima, Peru; [5]Mexico Centre for Clinical Research, HIV Research Department, Mexico City, Mexico; [6]Hospital of the University of Munich, Section for Infectious Diseases, Med. IV, Munich, Germany; [7]Bristol-Myers Squibb, Research and Development, Wallingford, USA; [8]Bristol-Myers Squibb, Research and Development, Princeton, USA

O433 **Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc**

Victor Kramer[1]; Said Hassounah[1]; Susan Colby-Germinario[1]; Thibault Mesplède[1]; Eric Lefebvre[2]; Mark Wainberg[1]

[1]McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; [2]Tobira Therapeutics, Inc., San Francisco, USA

O434 **48-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naïve HIV-Infected patients**

José Gatell[1]; Javier O. Morales-Ramirez[2]; Debbie P. Hagins[3]; Melanie Thompson[4]; Arasteh Keikawus[5]; Christian Hoffmann[6]; Sorin Rugina[7]; Olayemi Osiyemi[8]; Simona Escoriu[7]; Robin Dretler[9]; Charlotte Harvey[10]; Xia Xu[10]; Hedy Teppler[10]

[1]University of Barcelona, Hospital Clinic/IDIBAPS, Barcelona, Spain; [2]Clinical Research Puerto Rico, Clinical Research, San Juan, Puerto Rico; [3]Chatham Country Health, Country Health Department, Savannah, USA; [4]AIDS Research Consortium of Atlanta, AIDS Research Consortium of Atlanta, Atlanta, USA; [5]EPIMED/Vivantes Auguste-Viktoria-Klinikum, EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; [6]ICH Study Center, ICH Study Center, Hamburg, Germany; [7]Spitalul Clinic de Boli Infectioase, Spitalul Clinic de Boli Infectioase, Costanta, Romania; [8]Triple O Research Institute PA, West Palm Beach, USA; [9]Infectious Disease Specialists of Atlanta, Infectious Disease Specialists of Atlanta, Decatur, USA; [10]Merck & Co. Inc, Whitehouse Station, USA